Conference Day Two Agenda - March 27 2025
7:45 am Check In & Registration
8:40 am Chair’s Opening Remarks
8:45 am “SORTI”ing Out the Benefits of Leveraging SORT1 Targeting PDC to Unlock New Therapeutic Options in Oncology
Synopsis
- Discussing the SORT 1 receptor in cancer as a novel target and how exploitation of one of its main biological functions as a sorting/trafficking/scavenger protein facilitates rapid internalization of its ligands, within minutes, to deliver cytotoxic payloads inside cancer cells
- Considering the unique MOA and safety profile of TH1902, its potential for combination with other anti-cancer agents to improve efficacy outcomes, and discuss how it triggers immune infiltration via the cGAS/STING pathway to potentiate anti-PD-L1 immune mediated tumor cell killing
- Reviewing the discovery path of TH1902, from bench to bedside, and leverage the lessons learned to facilitate development of new SORT1 targeting PDC conjugates
Leveraging Peptide Drug Conjugates for Unlocking New Targets & Expanding Therapeutic Options in Oncology
9:15 am Overcoming Tumor Heterogeneity via Multispecific Targeting
Synopsis
- Scientific rationale for TwoStep Therapeutics’ multi-specific targeting agent “PIP” and how it enables broad applicability across solid tumors
- Overview of the PIP targeting platform, featuring modular formats with tunable PK and compatibility with diverse payloads
- Preclinical development of PIP-drug conjugates, their efficacy and safety, and comparison to conventional single-antigen targeting approaches
9:45 am Supporting Novel Bioconjugates From IND To Commercial Supply
Synopsis
- Serving the Innovators from the candidate selection to the IND, from Phase I to the long term commercial supply
- Overview on bioconjugation and fill/finish capabilities
- Delivering important updates on bioconjugation and fill-finish capacity
10:00 am Morning Break & Speed Networking
Synopsis
The ideal opportunity to network with many of the brightest minds in bioconjugate development, get to
know the current state-of-play in the field and form new connections for important in-depth conversations.
10:30 am TAC-001: A Toll-Like 9 Receptor Immune Agonist Conjugate for Solid Tumors
Synopsis
- Reviewing the scientific rationale behind TAC-001, a potent toll-like receptor 9 agonist (T-CpG) conjugated to an antibody against CD22
- Outlining the ongoing TAC-001 phase ½ clinical trial for advanced or metastatic solid tumors
- Exploring the potential of Tallac’s novel Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform for systemically administered immune agonist conjugates
11:00 am Bicycle Conjugates for Precision Targeting of Solid Tumors
Synopsis
- A novel peptide-based modality consisting of constrained peptides that form a bi-cyclic structure via ligation to a chemical scaffold
- Discovery using the Bicycle® phage display platform and have potential broad utility, allowing efficient and targeted delivery of different classes of payloads into tumors.
- Utilising Bicycle molecules are employed as targeting vectors to deliver toxins and radioisotopes to tumors for cancer imaging and therapy.
11:30 am CNS Delivery & Efficacy Evaluation of Novel Peptide siRNA Conjugates Targeting the Sortilin Receptor
Synopsis
- Analyzing structure-based design of Linear and Cyclic Peptides
- Reviewing the use of Non-Canonical Amino Acids for Enhanced siRNA Delivery
- Understanding the Distribution and Knockdown Efficiency of siRNA Targeted Transcripts
12:30 pm Networking Lunch
Highlighting Updates From the Novel Conjugate Landscape Within the Clinic – Leveraging the Lessons Learnt So Far
1:30 pm Bright Peak Immunoconjugates – A New Class Of Multi-Functional Biologics
Synopsis
- Overviewing Bright Peak’s immunoconjugate platform, designed to upgrade immune checkpoint therapy to the next level
- An update on BPT567 as the first PD1-IL18 immunoconjugate to enter the clinic
- Exploring the opportunity for novel biologic activity via Cis signaling with enhanced efficacy and safety
2:00 pm Technology for Degrader-Antibody Conjugates to Unlock Heterobifunctional Degraders Through mAb-like Pharmacokinetics & Excellent in vivo Efficacy
Synopsis
- Payloads of current marketed ADC are limited to three Modes of Action (MoAs): DNA binders, Tubulin- and TOP-I-Inhibitors
- Exploring novel conjugation technologies for stable conjugation and traceless release of heterobifunctional degraders
- Resulting DACs are homogenous with at high DAR, have excellent linker stability, and exhibit unprecedented in vivo PK and efficacy
Highlighting Cutting-Edge Discovery Platforms for Streamlining the Discovery & Design of Novel Bioconjugates
2:30 pm Discovery of Precision Antibody Drug Conjugates Employing Novel SMARCA2/4 Dual Degrader Payloads
3:00 pm Afternoon Break
Revolutionizing Novel Bioconjugate Synthesis & Process Development to Support Robust CMC for Developability, Product Quality & Cost Efficiency
4:00 pm Challenges in Process Development of Antibody Radio Conjugates (ARCs)
Synopsis
- Optimizing the conjugation methodologies
- Reviewing the formulation development of conjugated and radiolabeled molecules
- Understanding the analytical considerations
4:30 pm Pushing the Envelope: Developing Bi-Specific ADCs Using a Novel GlycOBI™ Platform
Synopsis
- Reviewing the advantages of Dual Targeting: Enhancing efficacy by targeting multiple tumor proteins simultaneously, combats resistance with varied mechanisms of action, and broadens the target patient populations
- Considering the benefits and Target Selection: Selecting the optimal targets and ideal formats remains complex, requiring precise identification of tumor-specific proteins for effective dual targeting
- An overview of the benefits of GlycOBI™ Platform: Producing homogenous ADCs without genetic modification, enhancing stability and anti-tumor activity with hydrophilic linkers, and simplifying the Chemistry, Manufacturing, and Controls (CMC) process